{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:40:58Z","timestamp":1790970058345,"version":"4.1.0"},"reference-count":41,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"unspecified","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,9,2]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to evaluate the suitability of the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) for measuring vision-related quality of life (VRQoL) in patients with Leber hereditary optic neuropathy receiving lenadogene nolparvovec gene therapy in three Phase III randomised controlled clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>VRQoL was assessed using the NEI-VFQ-25 at baseline (n=174) and 2 years after treatment (n=152). All participants received lenadogene nolparvovec in at least one eye. The scoring structure of the original NEI-VFQ-25 was evaluated for fit to the Rasch model, and a post hoc revision was created and psychometrically reevaluated. Stacked analysis was conducted to compare Rasch-revised scores at baseline and 2 years after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The original NEI-VFQ-25 exhibited multiple issues including limitations in response functioning and scale dimensionality. These issues were rectified by revising the NEI-VFQ25 into two separate unidimensional scales measuring \u2018Vision-related Activity Limitation\u2019 (VAL) and \u2018Socioemotional Functioning\u2019 (SEF). Participants\u2019 mean VAL score at baseline on a Rasch-transformed 0\u2013100 scale was 46.1 (11.7), improving to 48.4 (13.7) after treatment (\n                      <jats:italic>F<\/jats:italic>\n                      (1, 324) = 2.67, p=0.103). On the SEF scale, there was a significant difference 2 years after treatment, with participants improving from a mean score of 40.1 (14.1) at baseline to 49.6 (17.6) (\n                      <jats:italic>F<\/jats:italic>\n                      (1, 324) = 29.1, p&lt;0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The scoring structure of the original NEI-VFQ-25 has limitations that undermine its psychometric validity as a measure of VRQoL. Using the Rasch-revised NEI-VFQ-25, we determined that improvement in VRQoL after treatment with lenadogene nolparvovec was driven predominantly by an improvement in socioemotional functioning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002164","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T07:35:11Z","timestamp":1758180911000},"page":"e002164","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Rasch analysis of the NEI-VFQ-25: vision-related quality of life in Leber hereditary optic neuropathy after lenadogene nolparvovec gene therapy"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-0186","authenticated-orcid":false,"given":"Benson S","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK"},{"name":"Department of Medicine, The University of Auckland, Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Perot","sequence":"additional","affiliation":[{"name":"eXYSTAT, Malakoff, \u00cele-de-France, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Taiel","sequence":"additional","affiliation":[{"name":"Medical, GenSight Biologics SA, Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Yu-Wai-Man","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK"},{"name":"Moorfields Eye Hospital NHS Foundation Trust, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Horton","sequence":"additional","affiliation":[{"name":"Psychometric Laboratory for Health Sciences, University of Leeds, Leeds, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"2026010721211383000_10.1.e002164.1","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S162802"},{"key":"2026010721211383000_10.1.e002164.2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.7.1050"},{"key":"2026010721211383000_10.1.e002164.3","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.116.11.1496"},{"key":"2026010721211383000_10.1.e002164.4","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4494"},{"key":"2026010721211383000_10.1.e002164.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2009.11.019"},{"key":"2026010721211383000_10.1.e002164.6","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-017-0726-5","article-title":"Development of a new Rasch-based scoring algorithm for the National Eye Institute Visual Functioning Questionnaire to improve its interpretability","volume":"15","author":"Petrillo","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"2026010721211383000_10.1.e002164.7","unstructured":"Rasch G . Probabilistic models for some intelligence and attainment tests. ERIC, 1993."},{"key":"2026010721211383000_10.1.e002164.8","doi-asserted-by":"publisher","DOI":"10.1086\/346066"},{"key":"2026010721211383000_10.1.e002164.9","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41433-021-01535-9","article-title":"Natural history of patients with Leber hereditary optic neuropathy-results from the REALITY study","volume":"36","author":"Yu-Wai-Man","year":"2022","journal-title":"Eye (Lond)"},{"key":"2026010721211383000_10.1.e002164.10","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s11910-022-01246-y","article-title":"Developments in the Treatment of Leber Hereditary Optic Neuropathy","volume":"22","author":"Chen","year":"2022","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2026010721211383000_10.1.e002164.11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ajo.2023.09.005","article-title":"Leber Hereditary Optic Neuropathy Gene Therapy: Longitudinal Relationships Among Visual Function and Anatomical Measures","volume":"257","author":"Lam","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"2026010721211383000_10.1.e002164.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.12.012"},{"key":"2026010721211383000_10.1.e002164.13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz7423","article-title":"Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy","volume":"12","author":"Yu-Wai-Man","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026010721211383000_10.1.e002164.14","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/brain\/awac421","article-title":"Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy","volume":"146","author":"Newman","year":"2023","journal-title":"Brain (Bacau)"},{"key":"2026010721211383000_10.1.e002164.15","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000001367"},{"key":"2026010721211383000_10.1.e002164.16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/WCO.0000000000001343","article-title":"Clinical trials in Leber hereditary optic neuropathy: outcomes and opportunities","volume":"38","author":"Chen","year":"2025","journal-title":"Curr Opin Neurol"},{"key":"2026010721211383000_10.1.e002164.17","unstructured":"Mangione CM . Version 2000. The National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) Scoring Algorithm. National Eye Institute; 2023. Available: https:\/\/www.nei.nih.gov\/sites\/default\/files\/2019-06\/manual_cm2000.pdf"},{"key":"2026010721211383000_10.1.e002164.18","first-page":"1317","article-title":"Rasch Analysis of Repeated Measures","volume":"251","author":"Mallinson","year":"2011","journal-title":"RMT"},{"key":"2026010721211383000_10.1.e002164.19","doi-asserted-by":"crossref","unstructured":"Andrich D , Marais I . A course in rasch measurement theory. Berlin Heidelberg: Springer, 2019.","DOI":"10.1007\/978-981-13-7496-8"},{"key":"2026010721211383000_10.1.e002164.20","first-page":"205","article-title":"Detecting and evaluating the impact of multidimensionality using item fit statistics and principal component analysis of residuals","volume":"3","author":"Smith","year":"2002","journal-title":"J Appl Meas"},{"key":"2026010721211383000_10.1.e002164.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2008.10.007"},{"key":"2026010721211383000_10.1.e002164.22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/0146621616677520","article-title":"Critical Values for Yen\u2019s Q3: Identification of Local Dependence in the Rasch Model Using Residual Correlations","volume":"41","author":"Christensen","year":"2017","journal-title":"Appl Psychol Meas May"},{"key":"2026010721211383000_10.1.e002164.23","doi-asserted-by":"crossref","DOI":"10.3389\/fresc.2023.1208670","article-title":"Application of the Rasch measurement model in rehabilitation research and practice: early developments, current practice, and future challenges","volume":"4","author":"Tennant","year":"2023","journal-title":"Front Rehabil Sci"},{"key":"2026010721211383000_10.1.e002164.24","unstructured":"Linacre JM . Sample size and item calibration stability. RMT 1994;328."},{"key":"2026010721211383000_10.1.e002164.25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/WNO.0000000000001564","article-title":"The Impact of Leber Hereditary Optic Neuropathy on the Quality of Life of Patients and Their Relatives: A Qualitative Study","volume":"42","author":"Chen","year":"2022","journal-title":"J Neuroophthalmol"},{"key":"2026010721211383000_10.1.e002164.26","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s00417-021-05534-0","article-title":"Capturing the experiences of patients with inherited optic neuropathies: a systematic review of patient-reported outcome measures (PROMs) and qualitative studies","volume":"260","author":"Chen","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026010721211383000_10.1.e002164.27","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-3166"},{"key":"2026010721211383000_10.1.e002164.28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/WNO.0000000000000644","article-title":"Evaluation of Vision-Related Quality of Life in Chinese Patients With Leber Hereditary Optic Neuropathy and the G11778A Mutation","volume":"39","author":"Cui","year":"2019","journal-title":"J Neuroophthalmol"},{"key":"2026010721211383000_10.1.e002164.29","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.12.1.23","article-title":"Psychometric Validity of the Visual Function Index in Leber Hereditary Optic Neuropathy","volume":"12","author":"Chen","year":"2023","journal-title":"Transl Vis Sci Technol"},{"key":"2026010721211383000_10.1.e002164.30","doi-asserted-by":"publisher","DOI":"10.1177\/0264619615616260"},{"key":"2026010721211383000_10.1.e002164.31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.psym.2016.07.002","article-title":"An International Study of Emotional Response to Bilateral Vision Loss Using a Novel Graphical Online Assessment Tool","volume":"58","author":"Gale","year":"2017","journal-title":"Psychosomatics"},{"key":"2026010721211383000_10.1.e002164.32","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S113414"},{"key":"2026010721211383000_10.1.e002164.33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13023-021-01724-5","article-title":"Smoking and alcohol, health-related quality of life and psychiatric comorbidities in Leber\u2019s Hereditary Optic Neuropathy mutation carriers: a prospective cohort study","volume":"16","author":"Rabenstein","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"2026010721211383000_10.1.e002164.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(99)00045-3"},{"key":"2026010721211383000_10.1.e002164.35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s13023-024-03329-0","article-title":"Leber hereditary optic neuropathy in Slovenia: quality of life and costs from patient perspective","volume":"19","author":"Hawlina","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"2026010721211383000_10.1.e002164.36","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32296","article-title":"Leber hereditary optic neuropathy in Czechia and Slovakia: Quality of life and costs from patient perspective","volume":"10","author":"Bu\u0161\u00e1nyov\u00e1","year":"2024","journal-title":"Heliyon"},{"key":"2026010721211383000_10.1.e002164.37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13023-025-03737-w","article-title":"Leber hereditary optic neuropathy: utilities and carer burden from British and Irish participants","volume":"20","author":"Lawrence","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"2026010721211383000_10.1.e002164.38","unstructured":"Patient focused drug development: selecting, developing, or modifying fit-for purpose clinical outcome assessments. guidance for industry, food and drug administration staff, and other stakeholders. 2020."},{"key":"2026010721211383000_10.1.e002164.39","unstructured":"Patient focused drug development: selecting, developing, or modifying fit-for purpose clinical outcome assessments. guidance for industry, food and drug administration staff, and other stakeholders (draft guidance). US Department of Health and Human Services; 2022."},{"key":"2026010721211383000_10.1.e002164.40","unstructured":"Patient-focused drug development: methods to identify what is important to patients. guidance for industry, food and drug administration staff, and other stakeholders. US Department of Health and Human Services; 2022."},{"key":"2026010721211383000_10.1.e002164.41","unstructured":"Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making guidance for industry, food and drug administration staff, and other stakeholders. US Department of Health and Human Services; 2023."}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:22:13Z","timestamp":1767849733000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,17]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bmjophth-2025-002164"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002164","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}